Lung cancer recurrence in the thyroid, initially mistaken for thyroid cancer

This lung cancer diagnosis at a glance

Stage at diagnosis
Stage IV
Subtype
Adenocarcinoma
Biomarkers
EGFR exon 19 deletion; TTF-1-positive; Napsin A-positive; PAX8-negative; thyroglobulin staining limited to tumour cells adjacent to normal thyroid tissue
Sex
Male
Spread to
thyroid; cervical lymph nodes
Treatment
surgery, chemotherapy, targeted therapy and surveillance
Outcome
Cancer-Free / NED

Treatment course, step by step

  1. The original Stage IIB lung cancer was resected and followed by postoperative chemotherapy.
  2. Five years later, a left thyroid lobectomy and regional lymph-node dissection removed metastatic recurrence.
  3. Osimertinib began approximately 3 months after that surgery when right-lung nodules appeared.

What happened, in summary

A man in his 60s had previously undergone surgery for a 4.8 cm invasive non-mucinous adenocarcinoma of the lung. The tumour contained acinar, papillary and micropapillary patterns and was staged as pT2bN1cM0, Stage IIB. He then received postoperative chemotherapy and entered follow-up.

Five years later, ultrasound detected a thyroid nodule and an enlarged lymph node in his neck. The initial clinical concern was a new primary thyroid cancer. Cytology raised a different possibility: recurrence of the earlier lung cancer. He underwent removal of the left thyroid lobe with regional lymph-node dissection. The tumour had invaded nearby strap muscle and involved 2 lymph nodes. Its appearance closely matched the original lung adenocarcinoma. The cells were positive for TTF-1 and Napsin A and negative for PAX8, supporting metastatic lung cancer rather than a thyroid primary. Some tumour cells close to normal thyroid follicles also stained for thyroglobulin, an unusual finding that could have caused diagnostic confusion.

A postoperative PET/CT showed no apparent residual cancer, so observation was initially chosen. Three months later, CT identified several small right-lung nodules suspicious for further metastases. Molecular testing of the thyroid metastasis found an EGFR exon 19 deletion. He started osimertinib approximately 3 months after surgery.

By 5 months after the thyroid operation, he was disease free. His journey involved a rare metastatic site and required pathology, immunohistochemistry and genomic testing to distinguish recurrent lung adenocarcinoma from a separate thyroid cancer and guide targeted treatment.

Where this story comes from

This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full

How we source and attribute stories Accuracy and limitations

Collections this story belongs to

Similar lung cancer stories

These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer

Search more lung cancer stories